CXCL9 and breast cancer: It has been further reported that T cell immunoglobulin and mucin domain containing-3 (TIM-3), a negative regulator of T cell responses, is highly expressed by myeloid cells including cDC1s in the tumor microenvironment, and treatment with anti-TIM-3 monoclonal antibody upregulates the production of CXCL9 by cDC1s, resulting in CD8+ T cell expansion and suppression of tumor growth in a murine breast cancer model [50].